Channels

 

Special Offers & Promotions

 

 

Latest News

 

 

View Channel

New Products

 

 

View Channel

Video Presentations

 

 

View Channel

Separation Science

 

 

View Channel

Microscopy & Image Analysis

 

 

View Channel

Laboratory Automation & IT Solutions

 

 

View Channel

 

SeraCare Life Sciences Divests Biorepository Business

publication date: Jan 9, 2013
 | 
author/source: KENYONHOAG

SeraCare Life Sciences, a portfolio company of Linden Capital Partners serving the in vitro diagnostics and clinical laboratory markets, today announced that it has sold its biorepository, biobanking and laboratory services business to Precision Health Holdings, Inc

 

seracare logoThis Maryland-based business includes biorepository and biobanking services, AccuCell® products and certain laboratory services. “The sale of our Biorepository business is an important element in our growth strategy for SeraCare,” said Charles Mamrak, CEO of SeraCare. “We can now more freely serve our growing customer base in the in vitro diagnostics market and execute on our mission of improving quality of life by advancing a global understanding of disease.”

The transaction includes the transfer of Biorepository assets and employees. Financial terms of the transaction were not disclosed. SeraCare Life Sciences was advised by BroadOak Partners LLC and Kirkland & Ellis LLP during the transaction.


About SeraCare Life Sciences, Inc.


SeraCare partners with diagnostics researchers, IVD manufacturers and clinical laboratories to shape the future of medical diagnostics. Our innovative portfolio includes ACCURUN® quality controls, research panels, SeraCon® processed biological materials, specialty human blood products and characterized disease state materials. SeraCare helps bridge the gap between today’s diagnostic solutions and tomorrow’s emerging technologies for molecular diagnostics, next generation sequencing and companion diagnostics.

For more information, visit www.seracare.com.

 


About Linden Capital Partners


Linden Capital Partners is a Chicago-based private equity firm focused exclusively on leveraged buyouts in the healthcare and life science industries. Linden's strategy is based upon three elements: i) healthcare and life science industry specialization, ii) integrated private equity and operating expertise, and iii) strategic relationships with large corporations. Linden currently has investments in middle market platforms in the products, distribution, and services segments of healthcare.

For additional information about Linden, please refer to the firm's website at www.lindenllc.com.


 



 

Subscribe to any of our newsletters for the latest on new laboratory products, industry news, case studies and much more!

Newsletters from Lab Bulletin

 

Request your free copies HERE

 

 

 

Popular this Month

Top 10 most popular articles this month

 

 

Today's Picks

 


 

Looking for a Supplier?

Search by company or by product

 


Company Name:

Product:


 

 

 

 

Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd.


 

Media Partners

 

Exhibitions & Events